Literature DB >> 17393304

Renal dysfunction in heart failure patients: what is the evidence?

Heath E Saltzman1, Kumar Sharma, Paul J Mather, Sharon Rubin, Suzanne Adams, David Joshua Whellan.   

Abstract

Congestive heart failure (CHF) is an increasingly common medical condition and the fastest growing cardiovascular diagnosis in North America. Over one-third of patients with heart failure also have renal insufficiency. It has been shown that renal insufficiency confers worsened outcomes to patients with heart failure. However, a majority of the larger and therapy-defining heart failure medication and device trials exclude patients with advanced renal dysfunction. These studies also infrequently perform subgroup analyses based on the degree of renal dysfunction. The lack of information on heart failure patients who have renal insufficiency likely contributes to their being prescribed mortality and morbidity reducing medications and receiving diagnostic and therapeutic procedures at lower rates than heart failure patients with normal renal function. Inclusion of patients with renal insufficiency in heart failure studies and published guidelines for medication, device, and interventional therapies would likely improve patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393304     DOI: 10.1007/s10741-007-9006-5

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  88 in total

Review 1.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.

Authors:  Biff F Palmer
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

2.  Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.

Authors:  George Dangas; Ioannis Iakovou; Eugenia Nikolsky; Eve D Aymong; Gary S Mintz; Nicholas N Kipshidze; Alexandra J Lansky; Issam Moussa; Gregg W Stone; Jeffrey W Moses; Martin B Leon; Roxana Mehran
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

3.  Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function.

Authors:  C D Frances; H Noguchi; B M Massie; W S Browner; M McClellan
Journal:  Arch Intern Med       Date:  2000-09-25

4.  Renal insufficiency predicts the time to first appropriate defibrillator shock.

Authors:  Haitham Hreybe; Rana Ezzeddine; Maninder Bedi; William Barrington; Raveen Bazaz; Leonard I Ganz; Sandeep Jain; Ogundu Ngwu; Barry London; Samir Saba
Journal:  Am Heart J       Date:  2006-04       Impact factor: 4.749

5.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Authors:  P Ruggenenti; A Perna; G Gherardi; G Garini; C Zoccali; M Salvadori; F Scolari; F P Schena; G Remuzzi
Journal:  Lancet       Date:  1999-07-31       Impact factor: 79.321

6.  Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.

Authors:  J N Cohn; G Tognoni; R D Glazer; D Spormann; A Hester
Journal:  J Card Fail       Date:  1999-06       Impact factor: 5.712

7.  Preventing microalbuminuria in type 2 diabetes.

Authors:  Piero Ruggenenti; Anna Fassi; Anelja Parvanova Ilieva; Simona Bruno; Ilian Petrov Iliev; Varusca Brusegan; Nadia Rubis; Giulia Gherardi; Federica Arnoldi; Maria Ganeva; Bogdan Ene-Iordache; Flavio Gaspari; Annalisa Perna; Antonio Bossi; Roberto Trevisan; Alessandro R Dodesini; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

8.  Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.

Authors:  Javed Butler; Daniel E Forman; William T Abraham; Stephen S Gottlieb; Evan Loh; Barry M Massie; Christopher M O'Connor; Michael W Rich; Lynne Warner Stevenson; Yongfei Wang; James B Young; Harlan M Krumholz
Journal:  Am Heart J       Date:  2004-02       Impact factor: 4.749

9.  The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure.

Authors:  Niall G Mahon; Eugene H Blackstone; Gary S Francis; Randall C Starling; James B Young; Michael S Lauer
Journal:  J Am Coll Cardiol       Date:  2002-09-18       Impact factor: 24.094

10.  Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients.

Authors:  Jean-Christophe Luthi; W Dana Flanders; Michel Burnier; Bernard Burnand; William M McClellan
Journal:  BMC Nephrol       Date:  2006-03-06       Impact factor: 2.388

View more
  10 in total

Review 1.  Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.

Authors:  Xiaoliang Wang; Jiang Liu; Christopher A Drummond; Joseph I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2017-04-03       Impact factor: 6.902

Review 2.  The role of the kidney in acute and chronic heart failure.

Authors:  Gaetano Ruocco; Alberto Palazzuoli; Jozine M Ter Maaten
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

Review 3.  Comparing angiotensin II receptor blockers on benefits beyond blood pressure.

Authors:  Helmy M Siragy
Journal:  Adv Ther       Date:  2010-06-03       Impact factor: 3.845

Review 4.  Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially.

Authors:  Alberto Palazzuoli; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2011-11       Impact factor: 4.214

5.  Cigarette smoking causes epigenetic changes associated with cardiorenal fibrosis.

Authors:  Christopher A Drummond; Laura E Crotty Alexander; Steven T Haller; Xiaoming Fan; Jeffrey X Xie; David J Kennedy; Jiang Liu; Yanling Yan; Dawn-Alita Hernandez; Denzil P Mathew; Christopher J Cooper; Joseph I Shapiro; Jiang Tian
Journal:  Physiol Genomics       Date:  2016-10-27       Impact factor: 3.107

6.  Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.

Authors:  Pupalan Iyngkaran; Merlin Thomas; William Majoni; Nagesh S Anavekar; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2012-10-31       Impact factor: 2.041

7.  Reduction of Na/K-ATPase affects cardiac remodeling and increases c-kit cell abundance in partial nephrectomized mice.

Authors:  Christopher A Drummond; Moustafa Sayed; Kaleigh L Evans; Huilin Shi; Xiaoliang Wang; Steven T Haller; Jiang Liu; Christopher J Cooper; Zijian Xie; Joseph I Shapiro; Jiang Tian
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-04-18       Impact factor: 4.733

8.  Na/K-ATPase signaling regulates collagen synthesis through microRNA-29b-3p in cardiac fibroblasts.

Authors:  Christopher A Drummond; Michael C Hill; Huilin Shi; Xiaoming Fan; Jeffrey X Xie; Steven T Haller; David J Kennedy; Jiang Liu; Michael R Garrett; Zijian Xie; Christopher J Cooper; Joseph I Shapiro; Jiang Tian
Journal:  Physiol Genomics       Date:  2015-12-23       Impact factor: 3.107

Review 9.  Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.

Authors:  S Bouchez; F Fedele; G Giannakoulas; F Gustafsson; V-P Harjola; K Karason; M Kivikko; D von Lewinski; F Oliva; Z Papp; J Parissis; Piero Pollesello; G Pölzl; C Tschöpe
Journal:  Cardiovasc Drugs Ther       Date:  2018-12       Impact factor: 3.727

10.  Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial.

Authors:  Alain Cohen-Solal; Dipak Kotecha; Dirk J van Veldhuisen; Daphne Babalis; Michael Böhm; Andrew J Coats; Michael Roughton; Philip Poole-Wilson; Luigi Tavazzi; Marcus Flather
Journal:  Eur J Heart Fail       Date:  2009-08-01       Impact factor: 15.534

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.